Answers are grounded in this paper and cite their sources.
In this essay, we draw attention to some recent downsides and surprises of multiple sclerosis (MS) therapeutics. These include experiences with recent head-to-head trials of interferon-beta and glatiramer acetate, dose escalation trials, frustrating efforts with progressive MS trials, failures of smart concepts and designer therapies, and harsh lessons from newly observed adverse reactions.
No takes yet. Share an insight, caveat, or question.
Wiendl et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: